TY  - GEN
AU  - Kernt,Marcus
AU  - Thiele,Sarah
AU  - Neubauer,Aljoscha S
AU  - Koenig,Susanna
AU  - Hirneiss,Christoph
AU  - Haritoglou,Christos
AU  - Ulbig,Michael W
AU  - Kampik,Anselm
TI  - Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2
SN  - 1539-2864
PY  - 2012///1128
KW  - Adult
KW  - Aged
KW  - Angiogenesis Inhibitors
KW  - pharmacology
KW  - Antibodies, Monoclonal, Humanized
KW  - Benzenesulfonates
KW  - Cells, Cultured
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Humans
KW  - Immunohistochemistry
KW  - Indazoles
KW  - Light
KW  - Middle Aged
KW  - Neuropilin-1
KW  - genetics
KW  - Neuropilin-2
KW  - Neuropilins
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Phenylurea Compounds
KW  - Platelet-Derived Growth Factor
KW  - Protein Kinase Inhibitors
KW  - Pyridines
KW  - Pyrimidines
KW  - RNA, Messenger
KW  - metabolism
KW  - Ranibizumab
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Retinal Pigment Epithelium
KW  - drug effects
KW  - Reverse Transcriptase Polymerase Chain Reaction
KW  - Sorafenib
KW  - Sulfonamides
KW  - Vascular Endothelial Growth Factor A
KW  - Vascular Endothelial Growth Factor Receptor-1
KW  - Vascular Endothelial Growth Factor Receptor-2
N1  - Publication Type: Comparative Study; Journal Article
UR  - https://doi.org/10.1097/IAE.0b013e318240a558
ER  -